NCT03197480

Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME

Identifying Ocular and Systemic Biomarkers for Response to Aflibercept in Asian Patients With Centre Involving Diabetic Macular Edema: A Prospective Clinical Trial

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Singapore National Eye Centre · Other Government
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

To investigate whether ocular imaging and proteomic biomarkers; and systemic biochemical, metabolomic, and genetic biomarkers predict treatment response to intravitreal aflibercept in a cohort of patients with DME.

Detailed description

This is a prospective observational clinical trial with only the use of a standard care of drug, aflibercept. All study eyes will receive intravitreal aflibercept at the initial injection and x 4 monthly injections including at month 3.

Conditions

• Diabetic Macular Edema

Interventions

Type	Name	Description
DRUG	Aflibercept Injection [Eylea]	All subjects will receive 4 monthly intravitreal injections of aflibercept

Timeline

• Start date: 2019-04-17
• Primary completion: 2020-12-31
• Completion: 2021-03-01
• First posted: 2017-06-23
• Last updated: 2019-04-22

Locations

1 site across 1 country: Singapore

Regulatory

• FDA-regulated drug study